Study cohort | 1145 |
Demographics and comorbidities | |
Age years | 66 (56–74) |
Male | 455 (40) |
BMI kg·m–2 | 25 (22–28) |
Smoker/ex-smoker | 437 (38) |
CCI >1 | 373 (33) |
Aetiology of bronchiectasis | |
Idiopathic | 373 (34) |
Post-infective | 290 (26) |
COPD | 120 (11) |
Connective tissue disease | 89 (8) |
Immunodeficiency | 56 (5) |
ABPA | 54 (4.9) |
Asthma | 35 (3.2) |
Inflammatory bowel disease | 24 (2.2) |
Ciliary dysfunction | 20 (1.8) |
Aspiration | 14 (1.3) |
α1-antitrypsin deficiency | 10 (0.9) |
Congenital | 5 (0.5) |
Other | 20 (1.8) |
Disease severity | |
BSI score | 6 (4–11) |
FACED score | 2 (1–3) |
Radiological status | |
Reiff score | 4 (2–6) |
Clinical status | |
Daily cough | 899 (79) |
Daily sputum | 744 (65) |
Prior history of haemoptysis | 206 (18) |
MRC breathlessness scale | 2 (1–3) |
Long-term oxygen therapy | 86 (7.5) |
Exacerbations in the previous year | 2 (1–3) |
At least one hospitalisation in the previous year | 307 (27) |
Functional status | |
FEV1 % predicted | 75 (55–95) |
Microbiology | |
Chronic infection with at least one pathogen# | 455 (40) |
Haemophilus influenzae | 185 (16) |
Pseudomonas aeruginosa | 180 (15) |
Meticillin-sensitive Staphylococcus aureus | 61 (5.3) |
Moraxella catarrhalis | 51 (4.5) |
Streptococcus pneumoniae | 47 (4.1) |
Enterobacteriaceae | 29 (2.5) |
Meticillin-resistant Staphylococcus aureus | 21 (1.8) |
Escherichia coli | 14 (1.2) |
Klebsiella pneumoniae | 13 (1.1) |
Nontuberculous mycobacteria | 8 (0.7) |
Other | 31 (2.7) |
Laboratory findings | |
C-reactive protein mg·L−1 | 6 (4–8) |
Long-term antibiotic treatment | |
Either macrolide or inhaled antibiotics | 388 (34) |
Macrolide | 358 (31.3) |
Inhaled antibiotic treatment | 90 (7.9) |
Both macrolide and inhaled antibiotics | 60 (5.2) |